Multiple Ground Glass Opacities (GGOs)NCT03802981
A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
An observational study of Multiple Ground Glass Opacities (GGOs), run by Memorial Sloan Kettering Cancer Center at 32 sites in 2 countries.
Trial summary
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Multiple Ground Glass Opacities (GGOs)
- How many people
- 338 participants
- Where
- 32 sitesin 2 countries
- Study dates
- 9 Jan 2019to Jan 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with GGOs or mixed subsolid pulmonary nodules may be recruited from participating Thoracic Oncology Surgical Group (TSOG) sites, in accordance with local institutional practice and referral patterns, and assessed for eligibility based on the criteria listed below.
Who may be able to join
- Age greater than 18 years
- Have two or more GGOs on initial CT imaging
- GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension
- GGOs must be greater than half ground glass
- A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria.
Who cannot join
- Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment.
- The presence of any solid lesion ≥0.6 cm suspicious for malignancy.
- Patients who are actively undergoing treatment for other malignancies
Trial locations and contacts
32 sites in 2 countries.
32 sites in 2 countries
United States29 sites
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103
University of Michigan
Ann Arbor, Michigan, 48109
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Roswell Park Cancer Institute (Data Collection Only)
Buffalo, New York, 14263-0001
Rush University Medical Center (Data collection only)
Chicago, Illinois, 606012
Memorial Sloan Kettering Commack
Commack, New York, 11725
Duke University Medical Center
Durham, North Carolina, 27701
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Hartford Healthcare
Hartford, Connecticut, 06102
MD Anderson Cancer Center
Houston, Texas, 77030-4009
Baylor University Medical Center
Houston, Texas, 77030
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
New York Presbyterian Hospital
New York, New York, 10065
University of Pennsylvania (Data Collection Only)
Philadelphia, Pennsylvania, 19104
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Temple University
Philadelphia, Pennsylvania, 19140
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Mayo Clinic
Rochester, Minnesota, 55905
University of California San Diego
San Diego, California, 92103
George Washington University School of Medicine
St Louis, Missouri, 63110
Washington University School of Medicine
St Louis, Missouri, 63110
Stanford University Medical Center (Data collection only)
Stanford, California, 94305-5408
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Canada3 sites
McMaster University (Data Collection Only)
Hamilton, Ontario, L8N 3Z5
Centre Hospitalier de l'Université de Montreal
Montreal, Quebec, H2L 4M1
University Health Network
Toronto, Ontario, M5G 2C4
About this study
Official title: Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.
- Conditions
- Multiple Ground Glass Opacities (GGOs)
What is being measured
The primary outcome is the main question the study is designed to answer.
lung cancer-specific survival
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2019
- Study start9 Jan 2019
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multiple Ground Glass Opacities (GGOs)Studies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 338 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- M.D. Anderson Cancer Center, Brigham and Women's Hospital, Duke University, Mayo Clinic, Université de Montréal, University of Pittsburgh, University of Toronto, Washington University School of Medicine
- Responsible party
- Sponsor
- Investigators
- James Huang, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03802981
- Sponsor's protocol ID
- 18-541
- Status last verified
- Oct 2026
- First submitted
- 9 Jan 2019
- Last updated
- 23 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Publications
Huang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Evans N, Donahoe L, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M, Luketich J, Pennathur A, Petersen G, Ripley R, Rochefort M, Seder CW, Shrager J, Su S, Tong B, Shargall Y, Vaporciyan A, Waddell T, Weksler B, Wigle D, Yendamuri S, Jones DR. Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacities. J Thorac Cardiovasc Surg. 2025 Apr;169(4):1100-1107. doi: 10.1016/j.jtcvs.2024.09.054. Epub 2024 Oct 10.
PubMed 39395785
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
- ClinicalTrials.gov ID
- NCT03802981
- Acronym / sponsor ID
- 18-541
- Conditions
- Multiple Ground Glass Opacities (GGOs)
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 338 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- M.D. Anderson Cancer Center, Brigham and Women's Hospital, Duke University, Mayo Clinic, Université de Montréal, University of Pittsburgh, University of Toronto, Washington University School of Medicine
- Study start
- 9 Jan 2019 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 14 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with GGOs or mixed subsolid pulmonary nodules may be recruited from participating Thoracic Oncology Surgical Group (TSOG) sites, in accordance with local institutional practice and referral patterns, and assessed for eligibility based on the criteria listed below.
Key inclusion criteria (5 listed)
- Age greater than 18 years
- Have two or more GGOs on initial CT imaging
- GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension
- GGOs must be greater than half ground glass
- A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria.
Key exclusion criteria (3 listed)
- Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment.
- The presence of any solid lesion ≥0.6 cm suspicious for malignancy.
- Patients who are actively undergoing treatment for other malignancies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
lung cancer-specific survival
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Derived from this study: PubMed 39395785Huang J, Tan KS, Altorki N, Antonoff M, Blackmon S, Bueno R, Burt B, Demmy T, Evans N, Donahoe L, Harpole D, Jarrar D, Kozower B, Lanuti M, Liberman M, Lin J, Liou D, Liptay M, Luketich J, Pennathur A, Petersen G, Ripley R, Rochefort M, Seder CW, Shrager J, Su S, Tong B, Shargall Y, Vaporciyan A, Waddell T, Weksler B, Wigle D, Yendamuri S, Jones DR. Initial patient characteristics of Thoracic Surgical Oncology Group 102: A multicenter prospective registry of active surveillance in patients with multiple ground-glass opacities. J Thorac Cardiovasc Surg. 2025 Apr;169(4):1100-1107. doi: 10.1016/j.jtcvs.2024.09.054. Epub 2024 Oct 10.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James Huang, MD principal investigator
Memorial Sloan Kettering Cancer Center
32 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Ground Glass Opacities (GGOs), run by Memorial Sloan Kettering Cancer Center at 32 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 32 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
lung cancer-specific survival (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03802981, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.